Why the study?
Does intermittent intravenous outpatient administration of levosimendan reduce NT-proBNP, worsening of HRQoL, and heart failure hospitalizations in ambulatory patients with advanced systolic heart failure?
Does intermittent intravenous outpatient administration of levosimendan reduce NT-proBNP, worsening of HRQoL, and heart failure hospitalizations in ambulatory patients with advanced systolic heart failure?
Answers are grounded in this paper and cite their sources.
In a small pilot study, intermittent outpatient intravenous levosimendan showed potential benefits in reducing NT-proBNP, preventing HRQoL deterioration, and reducing hospitalizations in advanced systolic heart failure.
In this small pilot study, intermittent administration of levosimendan to ambulatory patients with advanced systolic heart failure reduced plasma concentrations of NT-proBNP, worsening of HRQoL and hospitalisation for heart failure. The efficacy and safety of this intervention should be confirmed in larger trials.
No takes yet. Share an insight, caveat, or question.
Comín‐Colet et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: